Publication
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Authors not recorded
Proc Natl Acad Sci U S A2001PMID 11504908PMC56958stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Prostate Neoplasmcivic_curation1.00
- drugTemsirolimuscivic_curation1.00
- genePTENcivic_curation1.00
- variantPTEN Losscivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 11504908
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PTEN Loss1 | ||||||||
| Temsirolimus | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID507In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779). PMID 11504908 · Neshat et al., 2001 · Open in CIViC | civic |